TOKYO, June 30 (Reuters) - Japanese drugmaker Eisai ( ESALF )

is developing a dementia treatment that it aims to

commercialise in the U.S. by fiscal 2030, the Nikkei reported on

Sunday.

The new drug targets a protein called tau, which causes

symptoms of Alzheimer's disease, the newspaper reported.

Eisai ( ESALF ) already has a dementia drug on the U.S. market called

Leqembi, co-developed with U.S. peer Biogen.

The companies announced on Friday that they would start

Leqembi sales in China, making that country the third where the

treatment is available after the U.S. and Japan.